Camlin Fine Sciences（532834）株式概要
カムリン・ファイン・サイエンシズ・リミテッドは、その子会社とともに、インド国内外で特殊化学品、原料、添加剤ブレンド製品の研究、開発、製造、販売に従事している。 詳細
532834 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Camlin Fine Sciences Limited 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | ₹121.35 |
| 52週高値 | ₹334.70 |
| 52週安値 | ₹96.30 |
| ベータ | 0.72 |
| 1ヶ月の変化 | 16.90% |
| 3ヶ月変化 | -14.84% |
| 1年変化 | -37.06% |
| 3年間の変化 | -29.81% |
| 5年間の変化 | -36.11% |
| IPOからの変化 | 1,327.65% |
最新ニュース
ナラティブの更新 • Apr 26
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).ナラティブの更新 • Apr 11
532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).ナラティブの更新 • Mar 25
532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).ナラティブの更新 • Mar 10
532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Recent updates
ナラティブの更新 • Apr 26
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).ナラティブの更新 • Apr 11
532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).ナラティブの更新 • Mar 25
532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).ナラティブの更新 • Mar 10
532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).ナラティブの更新 • Feb 24
532834: Upcoming Results Review Will Support Long Term Upside Potential
Analysts have adjusted their fair value estimate for Camlin Fine Sciences from ₹240 to ₹235, reflecting updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).ナラティブの更新 • Feb 09
532834: Upcoming Board And Director Decisions Will Support Long Term Upside
Analysts have maintained their fair value estimate for Camlin Fine Sciences at ₹240.00, with the small adjustments in discount rate and future P/E assumptions reflecting updated views on risk and valuation drivers rather than a change in the headline price target. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).ナラティブの更新 • Jan 25
532834: Director Reappointment And Steady Assumptions Will Support Long Term Upside
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹240.0 per share, with the unchanged target reflecting consistent assumptions on revenue growth, profit margin and future P/E, alongside a slightly updated discount rate input. What's in the News A board meeting is scheduled for Nov 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025, and to discuss other matters (Key Developments).ナラティブの更新 • Jan 11
532834: Governance Continuity And Stable Assumptions Will Support Long Term Upside
Analysts have kept their price target for Camlin Fine Sciences steady at ₹240.00. This reflects updated assumptions around a slightly higher discount rate and fine-tuned estimates for revenue growth, profit margin and future P/E, without a clear tilt in either a more optimistic or more cautious direction.ナラティブの更新 • Dec 24
532834: Share Swap And Governance Stability Will Drive Long Term Returns
Analysts have maintained their price target for Camlin Fine Sciences at ₹240.00, with only marginal tweaks to the underlying model inputs. This reflects steady confidence in the company’s growth and profitability trajectory.ナラティブの更新 • Dec 10
532834: Share Swap Acquisition Will Drive Long Term Returns
Analysts have modestly maintained their outlook on Camlin Fine Sciences, keeping the price target broadly unchanged near ₹240, as small tweaks to the discount rate and forward earnings assumptions continue to support a steady long term growth narrative. What's in the News Board meeting scheduled for November 10, 2025, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider the reappointment of Mahabaleshwar Palekar as a non executive independent director (Key Developments).ナラティブの更新 • Nov 26
532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns
Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.ナラティブの更新 • Nov 11
532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure
Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.新しいナラティブ • Sep 04
Tariff Benefits And Safety Trends Will Boost US And Europe
Key Takeaways Plant restarts and easing exceptional expenses are set to improve margins, with structural growth driven by global demand for compliant, high-quality food additives. Favorable trade barriers and China+1 supply diversification position Camlin Fine Sciences for market share gains, margin expansion, and reduced dependence on legacy products.株主還元
| 532834 | IN Chemicals | IN 市場 | |
|---|---|---|---|
| 7D | 2.1% | 2.1% | 0.7% |
| 1Y | -37.1% | -2.0% | -0.3% |
業界別リターン: 532834過去 1 年間で-2 % の収益を上げたIndian Chemicals業界を下回りました。
リターン対市場: 532834は、過去 1 年間で-0.3 % のリターンを上げたIndian市場を下回りました。
価格変動
| 532834 volatility | |
|---|---|
| 532834 Average Weekly Movement | 8.5% |
| Chemicals Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.8% |
安定した株価: 532834 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: 532834の 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1931 | 661 | Ashish Dandekar | www.camlinfs.com |
カムリン・ファイン・サイエンシズ社（Camlin Fine Sciences Limited）は、その子会社とともに、インド国内外で特殊化学品、原料、添加物ブレンド製品の研究、開発、製造、販売を行っている。同社は、ブチルヒドロキシトルエンやパルミチン酸アスコルビルなどの酸化防止剤、乳化剤、防カビ剤、抗菌剤、毒素結合剤、ペレット結合剤、殺菌剤、活力剤、保存料、増粘剤、成長促進剤、XtendraやNaSureブランドで保存性を高めるために使用されるミックストコフェロール、緑茶抽出物、ローズマリー抽出物などの植物由来の酸化防止剤を含む保存性ソリューションを提供している。また、バニリンやエチルバニリンなどの香気成分、健康・ウェルネス製品、ハイドロキノンやカテコールなどの機能性化学品も提供している。同社の製品は、食品・飲料、ペットフード、動物栄養、レンダリング、ヘルス＆ウェルビーイング、化学、バイオ燃料、アロマテクニカル、フレグランス、フレーバー産業で使用されている。以前はCamlin Fine Chemicals Limitedとして知られていたが、2011年8月にCamlin Fine Sciences Limitedに社名変更。Camlin Fine Sciences Limitedは1931年に設立され、インドのムンバイに本社を置く。
Camlin Fine Sciences Limited 基礎のまとめ
| 532834 基礎統計学 | |
|---|---|
| 時価総額 | ₹23.31b |
| 収益（TTM） | -₹140.89m |
| 売上高(TTM) | ₹17.78b |
1.3x
P/Sレシオ-165.4x
PER（株価収益率532834 は割高か？
公正価値と評価分析を参照収益と収入
| 532834 損益計算書（TTM） | |
|---|---|
| 収益 | ₹17.78b |
| 売上原価 | ₹9.86b |
| 売上総利益 | ₹7.92b |
| その他の費用 | ₹8.06b |
| 収益 | -₹140.89m |
直近の収益報告
Dec 31, 2025
次回決算日
May 26, 2026
| 一株当たり利益（EPS） | -0.73 |
| グロス・マージン | 44.54% |
| 純利益率 | -0.79% |
| 有利子負債／自己資本比率 | 78.1% |
532834 の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 22:47 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Camlin Fine Sciences Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9
| アナリスト | 機関 |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| Satish Kumar | CGS International |